Zehra Okat
Zehra Okat has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Asiye Gok Yurttas
Department of Medical Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul 34403, Türkiye
1 shared publication - Ayşe Akgül Işık1 shared publication
- Burcu Biltekin
Department of Histology and Embryology, Faculty of Medicine, Istanbul Atlas University, Istanbul 34403, Turkey
1 shared publication - Busra Yaprak Bayrak
Kocaeli University School of Medicine
1 shared publication Elif Kurt
1 shared publication- Fahriye Çoban
Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, European University of Lefke, Lefke, Northern Cyprus, TR-10 Mersin, Turkey
1 shared publication
Latest Publications
- Open Access
- 23 March 2023
- Published by Özgür Yayınları
- p. 169-178
Kanser Hastalığı ve Rehabilitasyonu
Kanser bir organ veya dokudaki hücrelerin düzensiz ve kontrolsüz olarak bölünüp çoğalması sonucu ile oluşan tümörlere denir. Genel anlamda ise kanser vücudumuzun çeşitli bölgelerindeki hücrelerin kontrolsüz çoğalması ile normalde olmayan bir oluşum meydana getirirler. Bu yeni ve ekstra hücreler durmadan bölünerek tümör adı verilen kitleleri oluşturmaktadır. Kanser, metastaz adı verilen bir süreçle vücuda yayılır. Kanser hücreleri orijinal konumlarından ayrılarak kan veya lenf sisteminden geçerek vücudun diğer bölgelerinde yeni tümörler oluştururlar. Kanser metastazları en yaygın olarak kemiklerde, karaciğerde veya akciğerlerde bulunur. Kanser tedavisinde genel olarak ve en yaygın kullanılan tedavi yöntemlerinden immünoterapi, radyoterapi, kemoterapi ve cerrahi tedavi uygulanmaktadır. Bu tedavilerin hastayı etkileyebilecek yan etkileri olmakla beraber koruyucu ve restoratif evresinde büyük öneme sahiptir. Kansere sahip bireylerde bağımsızlığı ve fonksiyonel kapasiteyi artırmak ve yaşam kalitesini iyileştirmek için kanser rehabilitasyonu da önemli bir yere sahiptir. Kanser Rehabilitasyonu hem sağlık bakımı maliyeti açısından hem de kansere yakalanma riskini azaltmaktadır. Birçok Kanser Rehabilitasyon programı, lenfödem, üst ekstremite fonksiyonel bozukluğu, yürüme ve denge disfonksiyonu gibi spesifik hasta ihtiyaçlarına yönelik hizmetler sunsa da, genel olarak fonksiyonel kapasiteyi artırma, büyük kas gruplarını kuvvetlendirme, ağrıyı azaltmak, esneklik ve dengeyi artırarak bağımsızlık seviyesini artırmaya yöneliktir.
- 23 March 2023
- Published by Özgür Yayınları
- p. 169-178
Open AccessKanser Hastalığı ve Rehabilitasyonu
Kanser bir organ veya dokudaki hücrelerin düzensiz ve kontrolsüz olarak bölünüp çoğalması sonucu ile oluşan tümörlere denir. Genel anlamda ise kanser vücudumuzun çeşitli bölgelerindeki hücrelerin kontrolsüz çoğalması ile normalde olmayan bir oluşum meydana getirirler. Bu yeni ve ekstra hücreler durmadan bölünerek tümör adı verilen kitleleri oluşturmaktadır. Kanser, metastaz adı verilen bir süreçle vücuda yayılır. Kanser hücreleri orijinal konumlarından ayrılarak kan veya lenf sisteminden geçerek vücudun diğer bölgelerinde yeni tümörler oluştururlar. Kanser metastazları en yaygın olarak kemiklerde, karaciğerde veya akciğerlerde bulunur. Kanser tedavisinde genel olarak ve en yaygın kullanılan tedavi yöntemlerinden immünoterapi, radyoterapi, kemoterapi ve cerrahi tedavi uygulanmaktadır. Bu tedavilerin hastayı etkileyebilecek yan etkileri olmakla beraber koruyucu ve restoratif evresinde büyük öneme sahiptir. Kansere sahip bireylerde bağımsızlığı ve fonksiyonel kapasiteyi artırmak ve yaşam kalitesini iyileştirmek için kanser rehabilitasyonu da önemli bir yere sahiptir. Kanser Rehabilitasyonu hem sağlık bakımı maliyeti açısından hem de kansere yakalanma riskini azaltmaktadır. Birçok Kanser Rehabilitasyon programı, lenfödem, üst ekstremite fonksiyonel bozukluğu, yürüme ve denge disfonksiyonu gibi spesifik hasta ihtiyaçlarına yönelik hizmetler sunsa da, genel olarak fonksiyonel kapasiteyi artırma, büyük kas gruplarını kuvvetlendirme, ağrıyı azaltmak, esneklik ve dengeyi artırarak bağımsızlık seviyesini artırmaya yöneliktir.
- 10 October 2018
- Published by AccScience Publishing in Eurasian Journal of Medicine and Oncology
- Vol. 2 (4) , 189-197
Molecular Dynamics of Estrogen Receptors
Nuclear receptor (NR) superfamily is located in the transcriptional regulator class. Owing to their important role in controlling many physiological and pathological events, it has become the most important therapeutic targets inclinical trials. Although it is used successfully in many cases, allowing receptor-modulating drugs, owing to targeted therapy resistance, the mechanisms of NRs that work for generating new drugs are still up to date. Most successful target therapy for controlling the activity of the receptor was conducted based on the NR signaling pathway. In this review, estrogen receptor (ER) subtypes, ER domain structure and general features, ER molecular signaling mechanisms, ER degradation occurring with the ubiquitin–proteasome pathway, ER degradation triggered by basal and ligand, effect of ER concentration in response to estrogen, and ER alpha molecular background of the action of agonists and antagonists are explained in detail. The comprehensive information in this article is intended to provide a clearer understanding of the receptor function in the control of key points. We believe that it would be useful for future therapeutic approaches.
- 10 October 2018
- Published by AccScience Publishing in Eurasian Journal of Medicine and Oncology
- Vol. 2 (4) , 189-197
Molecular Dynamics of Estrogen Receptors
Nuclear receptor (NR) superfamily is located in the transcriptional regulator class. Owing to their important role in controlling many physiological and pathological events, it has become the most important therapeutic targets inclinical trials. Although it is used successfully in many cases, allowing receptor-modulating drugs, owing to targeted therapy resistance, the mechanisms of NRs that work for generating new drugs are still up to date. Most successful target therapy for controlling the activity of the receptor was conducted based on the NR signaling pathway. In this review, estrogen receptor (ER) subtypes, ER domain structure and general features, ER molecular signaling mechanisms, ER degradation occurring with the ubiquitin–proteasome pathway, ER degradation triggered by basal and ligand, effect of ER concentration in response to estrogen, and ER alpha molecular background of the action of agonists and antagonists are explained in detail. The comprehensive information in this article is intended to provide a clearer understanding of the receptor function in the control of key points. We believe that it would be useful for future therapeutic approaches.
- Open Access
- 19 September 2018
- Published by MedCrave Group Kft. in International Physical Medicine & Rehabilitation Journal
- Vol. 3 (5) , 1
The connection between microsomal epoxide hydrolase enzyme and cancer risk
- 19 September 2018
- Published by MedCrave Group Kft. in International Physical Medicine & Rehabilitation Journal
- Vol. 3 (5) , 1
Open AccessThe connection between microsomal epoxide hydrolase enzyme and cancer risk
- 27 May 2018
- Published by Marmara University in Marmara Medical Journal
- Vol. 31 (2) , 61-67
CYP 2D6* 4 polymorphism in Polycythemia vera patients in Turkish population
Objective: Many studies have shown the association ofsusceptibility to several cancers with gene encoding enzymes’polymorphisms which engage in xenobiotics’ biotransformation.In this study, the main purpose is to search the relation betweencytochrome P450 (CYP) 2D6* 4 polymorphisms and Polycythemiavera (PV) incidence in Turkish population.Materials and Methods: In this research article, 80Polycthemia vera (PV) cases and 76 control samples have beenused for the analysis of CYP 2D6* 4 polymorphism. The researchhas been performed by the methods of polymerase chain reaction(PCR)-restriction fragment length polymorphism (RFLP).Results: As a result, when patients and controls werecompared in terms of CYP 2D6* 4 poor metabolizer (PM) andheterozygous extensive metabolizer (HEM) genotype frequency,it has been found that the patients have 1.35% PM and 32.43%HEM frequency, and controls have 2.63% PM and 21.05% HEMfrequency. The correlation between the results of CYP 2D6genotype analysis and the risk of disease in patients and controlswas examined. We found that PM, HEM and extensive metabolizer(EM) genotypes were unrelated with the risk of PV (OR 0.51, 95%CI 0.04-5.71, OR 1.80, 95% CI 0.86-3.75, χ2 1.93, P: 0.164, OR0.61, 95% CI 0.30-1.24, χ2 1.40, P: 0.235).Conclusion: Our results suggested that the CYP 2D6*4 polymorphism, in the studied population, does not play animportant role in PV etiology.
- 27 May 2018
- Published by Marmara University in Marmara Medical Journal
- Vol. 31 (2) , 61-67
CYP 2D6* 4 polymorphism in Polycythemia vera patients in Turkish population
Objective: Many studies have shown the association ofsusceptibility to several cancers with gene encoding enzymes’polymorphisms which engage in xenobiotics’ biotransformation.In this study, the main purpose is to search the relation betweencytochrome P450 (CYP) 2D6* 4 polymorphisms and Polycythemiavera (PV) incidence in Turkish population.Materials and Methods: In this research article, 80Polycthemia vera (PV) cases and 76 control samples have beenused for the analysis of CYP 2D6* 4 polymorphism. The researchhas been performed by the methods of polymerase chain reaction(PCR)-restriction fragment length polymorphism (RFLP).Results: As a result, when patients and controls werecompared in terms of CYP 2D6* 4 poor metabolizer (PM) andheterozygous extensive metabolizer (HEM) genotype frequency,it has been found that the patients have 1.35% PM and 32.43%HEM frequency, and controls have 2.63% PM and 21.05% HEMfrequency. The correlation between the results of CYP 2D6genotype analysis and the risk of disease in patients and controlswas examined. We found that PM, HEM and extensive metabolizer(EM) genotypes were unrelated with the risk of PV (OR 0.51, 95%CI 0.04-5.71, OR 1.80, 95% CI 0.86-3.75, χ2 1.93, P: 0.164, OR0.61, 95% CI 0.30-1.24, χ2 1.40, P: 0.235).Conclusion: Our results suggested that the CYP 2D6*4 polymorphism, in the studied population, does not play animportant role in PV etiology.